Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $11,328,000 | reported | |
| FY 2024 | 2024-12-31 | $13,036,000 | reported | |
| FY 2023 | 2023-12-31 | $18,765,000 | reported | |
| FY 2022 | 2022-12-31 | $19,805,000 | reported | |
| FY 2021 | 2021-12-31 | $15,820,000 | reported | |
| FY 2020 | 2020-12-31 | $7,528,000 | reported |
Faeth Therapeutics, Inc. · CIK 1829802 · Engraved from SEC EDGAR
FY2025 figures · derived
Faeth Therapeutics, Inc. is the 230th largest of the 552 covered companies the SEC files under this code, by market cap. SIC 2834
Latest filing Nov 17, 2026
The us-gaap concepts with the most facts on file for this company.
Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2023 | — | $10.38M | $10.38M | — | 25.07M sh | −19.1% | — |
78 managers · Quarter ended Sep 30, 2026All holders ›
41